Science brief
Israeli Discoveries Redefine Biology, Food, and Medicine
Breakthroughs at Weizmann and Technion yield air-to-food microbes, self-healing cellular pathways, and promising Alzheimer's immunotherapies.
Science
Weizmann scientists have engineered bacteria to synthesize food from carbon dioxide — a milestone that could bypass traditional agricultural dependencies on land and water.
BackgroundGlobal agricultural systems are increasingly vulnerable to climate change, extreme weather, and severe fertilizer supply shocks. Research into microbial synthetic food seeks to bypass these risks entirely by creating nutrient-rich proteins without relying on arable land or fresh water.
- Professor Ron Milo's lab modified the bacteria's metabolic pathway by implementing specialized cellular structures, which drastically accelerates their carbon absorption and converts gas into complex organic molecules.
- The long-term program aims to manufacture sustainable protein feeds for livestock and eventually humans, which could eliminate the environmental pressure of clearing forests for soy and grain crops.
- The research was unveiled at the Israel Society of Ecology and Environmental Sciences conference, sparking immediate investment discussions with sustainable food ventures looking to scale the technology.
Science
Technion researchers discovered mature corneal cells can reprogram themselves into active stem cells — upending the biological dogma that stem cell depletion is irreversible.
BackgroundStem cells act as the body's primary self-repair mechanism, but scientists believed that once aging or injury depleted these cells, tissues permanently lost their healing capacity. Traditional regenerative medicine has therefore focused on importing external stem cells rather than triggering local mature cells to repair themselves.
- The research team developed a specialized fluorescent tracking system to monitor live tissue responses, allowing them to watch mature cells reprogram themselves in real time.
- Even after scientists completely destroyed the local corneal stem cell population, mature cells reverted to a stem-like state to preserve long-term tissue function, preventing permanent blindness in the test subjects.
- The molecular insight could pave the way for regenerative therapies that repair damaged human organs internally, bypassing the need for complex and controversial external cell transplants.
Science
A Weizmann-designed immunotherapy has successfully cleared initial human safety trials — validating a peripheral immune-boosting strategy as a viable alternative to failed plaque-targeting drugs.
BackgroundMost historical Alzheimer's treatments focused on directly clearing amyloid plaques from the brain, a strategy that has repeatedly failed to stop cognitive decline. The Weizmann-designed approach instead leverages peripheral immunotherapy to stimulate the patient's own immune system, mobilizing it to clear toxic waste from brain tissue.
- The Phase 1b clinical trial evaluated 40 patients across sites in Israel, the UK, and the Netherlands to establish safety and optimal dosing parameters.
- Developed by Israeli startup ImmunoBrain Checkpoint, the specialized antibody is designed to bypass the blood-brain barrier by activating the body's immune cells to repair neural pathways.
- The drug successfully met its primary safety endpoints with no severe adverse side effects, clearing the regulatory hurdles necessary to initiate larger, multi-country efficacy trials.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.